仙琚製藥(002332.SZ):丙酸氟替卡松原料藥通過藥品GMP現場檢查
格隆匯1月15日丨仙琚製藥(002332.SZ)公佈,根據浙江省藥品監督管理局近日發佈的“浙江省藥品GMP檢查結果公告(2020年第1號)”,公司丙酸氟替卡松原料藥通過現場檢查,現將有關信息公告如下:
企業名稱:浙江仙琚製藥股份有限公司;地址:浙江省台州市仙居縣仙藥路1號;檢查範圍:原料藥(丙酸氟替卡鬆);檢查日期:2019年12月12日至2019年12月14日;結論:經現場檢查,公司丙酸氟替卡松原料藥生產符合《藥品生產質量管理規範(2010年修訂)》要求。
此次通過現場檢查,有利於公司提升高品質原料藥的生產能力,豐富原料藥品種。公司將保持穩定的生產管理和質量保證體系,更好地滿足市場需求,保障公司可持續發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.